运用RT-PCR方法对结直肠癌及肝转移相关基因进一步的验证研究
|
摘要
目的:
运用Real time-PCR方法开展对以往全基因芯片筛查所得的结直肠癌和结直肠癌肝转移相关基因进一步的验证研究。
方法:
选取复旦大学附属中山医院结直肠癌专业组2004年3月～2007年10月手术的结直肠正常组织及结直肠癌组织冻存标本共80例,分为结直肠正常组织组(n=20),结直肠癌无肝转移组(无肝转移组,n=20),结直肠癌同时性肝转移组(同时性肝转移组,n=20)与结直肠癌异时性肝转移组(异时性肝转移组,n=20)。采用基于SYBR green的荧光染料掺入法real-time PCR检测所有标本中84个基因(源自以往全基因芯片筛查所得的结直肠癌和结直肠癌肝转移相关基因)的相对表达量,比较无肝转移组与同时性肝转移组、无肝转移组与异时性肝转移组、同时性肝转移组与异时性肝转移组基因表达差异。另外,分别比较结直肠正常组织组与无肝转移组、同时性肝转移组及异时性肝转移组之间的基因表达差异。运用t检验方法对各组△CT值行组内比较,2~(-△△CT)法分析基因相对表达量。
结果:
在结直肠癌肝转移相关基因研究中共得到4个差异基因,其中表达上调基因3个,下调基因1个。同时性肝转移组较无肝转移组SRC基因的表达升高2.2倍(p=0.016);同时性肝转移组AZGP1基因的表达较无肝转移组升高2.36倍(p=0.025);同时性肝转移组IQCA基因较无肝转移组上调3.50倍(p=0.015);HCA112基因在异时性肝转移组较无肝转移组下调0.61倍(p=0.040)。
在所有结直肠癌组织与结直肠正常组织基因表达差异研究中,共获得24个差异基因,其中下调基因20个,分别为EGFL6、HRASLS、HFE、DTX1、SLC16A7、MAF、ST70T1、PLCL2、ISL1、SLC30A7、MAGED4、CAMK2N1,TDGF1、IL28RA、CYP51A1、SCIN、CDKL1、AQP11、GPR160、CUGBP1;上调基因4个,分别为PLEKHH1、SATB2、AP1G2、MFSD2。
结论
1 SRC,AZGP1,IQCA基因在结直肠癌组织中的上调表达可能与同时性肝转移相关;
2 HCA112基因在结直肠癌组织中的下调表达可能与异时性肝转移相关;
3 EGFL6、HRASLS、HFE、DTX1、SLC16A7、MAF、ST70T1、PLCL2、ISL1、SLC30A7、MAGED4、CAMK2N1、TDGF1、IL28RA、CYP51A1、SCIN、CDKL1、AQP11、GPR160、CUGBP1基因的下调表达可能与结直肠癌的发生有关;
4 PLEKHH1、SATB2、AP1G2、MFSD2基因的上调表达可能与结直肠癌的发生有关;
5上述基因的功能,与结直肠癌及结直肠癌肝转移的关系需要进一步的验证研究。
Objective:
To verify genes screened by gene expression profiling chips which are possibly related to colorectal cancer and liver metastasis of colorectal cancer(LMCC) by means of real-time PCR.
Methods:
Between Mar 2004 and Oct 2007,80 patients,who underwent colorectal cancer surgery in colorectal professional group of Zhongshan Hospital, were assigned to research groups.Four groups of colorectal normal tissue (n=20),colorectal cancer without liver metastasis(n=20),colorectal cancer with synchronia liver metastasis(n=20),colorectal cancer with heterochronia liver metastasis(n=20) were built up.Correspondence cycle threshold(CT) value of 84 genes expressed in the 80 specimen were analyzed using real-time PCR method based on SYBR green.We compared the expressed quantity between colorectal cancer without liver metastasis and synchronia liver metastasis,colorectal cancer without liver metastasis and heterochronia liver metastasis,synchronia liver metastasis and heterochronia liver metastasis,colorectal normal tissue and colorectal tumor tissue.T test was used to compare the difference among groups, 2~(-△△CT) method was used to analyze the correspondence expressed quantity.
Results:
Four differentially expressed genes were found probably related to colorectal cancer liver metastasis,including three up regulation genes and one down regulation genes.SRC gene is up regulated 2.2 times in colorectal cancer with synchronia liver metastasis(p=0.016),AZGP1 is 2.4 times(p=0.025) up regulated in synchronia liver metastasis,IQCA is 3.5 times(p=0.015) up regulated in synchronia liver metastasis.HCA112 gene is down regulated 0.61 times(p=0.04) in colorectal cancer with heterochronia liver metastasis.
24 differentially expressed genes were found probably related to colorectal cancer.20 genes are down regulated such as EGFL6,HRASLS,HFE, DTX1,SLC16A7,MAF,ST70T1,PLCL2,ISL1,SLC30A7,MAGED4,CAMK2N1,TDGF1, IL28RA,CYP51A1,SCIN,CDKL1,AQP11,GPR160 and CUGBP1,4 genes are up rugulated such as PLEKHH1,SATB2,AP1G2 and MFSD2.
Conclusion"
1) Up regulation of gene SRC,AZGP1 and IQCA in colorectal cancer probably have relationship with colorectal cancer synchronia liver metastasis.
2) Down regulation of gene HCA112 probably have relationship with heterochronia liver metastasis.
3) Down regulation of gene EGFL6,HRASLS,HFE,DTX1,SLC16AT,MAF, STT0T1,PLCL2,ISL1,SLC3OAT,MAGED4,CAMK2N1,TDGF1,IL28RA,CYP51A1, SCIN,CDKL1,AQP11,GPR160 and CUGBP1 may concerned with the development of colorectal cancer.
4) Up regulation of gene PLEKHH1,SATB2,AP1G2 and MFSD2 may concerned with the development of colorectal cancer.
5) All genes need further research.
运用Real time-PCR方法开展对以往全基因芯片筛查所得的结直肠癌和结直肠癌肝转移相关基因进一步的验证研究。
方法:
选取复旦大学附属中山医院结直肠癌专业组2004年3月～2007年10月手术的结直肠正常组织及结直肠癌组织冻存标本共80例,分为结直肠正常组织组(n=20),结直肠癌无肝转移组(无肝转移组,n=20),结直肠癌同时性肝转移组(同时性肝转移组,n=20)与结直肠癌异时性肝转移组(异时性肝转移组,n=20)。采用基于SYBR green的荧光染料掺入法real-time PCR检测所有标本中84个基因(源自以往全基因芯片筛查所得的结直肠癌和结直肠癌肝转移相关基因)的相对表达量,比较无肝转移组与同时性肝转移组、无肝转移组与异时性肝转移组、同时性肝转移组与异时性肝转移组基因表达差异。另外,分别比较结直肠正常组织组与无肝转移组、同时性肝转移组及异时性肝转移组之间的基因表达差异。运用t检验方法对各组△CT值行组内比较,2~(-△△CT)法分析基因相对表达量。
结果:
在结直肠癌肝转移相关基因研究中共得到4个差异基因,其中表达上调基因3个,下调基因1个。同时性肝转移组较无肝转移组SRC基因的表达升高2.2倍(p=0.016);同时性肝转移组AZGP1基因的表达较无肝转移组升高2.36倍(p=0.025);同时性肝转移组IQCA基因较无肝转移组上调3.50倍(p=0.015);HCA112基因在异时性肝转移组较无肝转移组下调0.61倍(p=0.040)。
在所有结直肠癌组织与结直肠正常组织基因表达差异研究中,共获得24个差异基因,其中下调基因20个,分别为EGFL6、HRASLS、HFE、DTX1、SLC16A7、MAF、ST70T1、PLCL2、ISL1、SLC30A7、MAGED4、CAMK2N1,TDGF1、IL28RA、CYP51A1、SCIN、CDKL1、AQP11、GPR160、CUGBP1;上调基因4个,分别为PLEKHH1、SATB2、AP1G2、MFSD2。
结论
1 SRC,AZGP1,IQCA基因在结直肠癌组织中的上调表达可能与同时性肝转移相关;
2 HCA112基因在结直肠癌组织中的下调表达可能与异时性肝转移相关;
3 EGFL6、HRASLS、HFE、DTX1、SLC16A7、MAF、ST70T1、PLCL2、ISL1、SLC30A7、MAGED4、CAMK2N1、TDGF1、IL28RA、CYP51A1、SCIN、CDKL1、AQP11、GPR160、CUGBP1基因的下调表达可能与结直肠癌的发生有关;
4 PLEKHH1、SATB2、AP1G2、MFSD2基因的上调表达可能与结直肠癌的发生有关;
5上述基因的功能,与结直肠癌及结直肠癌肝转移的关系需要进一步的验证研究。
Objective:
To verify genes screened by gene expression profiling chips which are possibly related to colorectal cancer and liver metastasis of colorectal cancer(LMCC) by means of real-time PCR.
Methods:
Between Mar 2004 and Oct 2007,80 patients,who underwent colorectal cancer surgery in colorectal professional group of Zhongshan Hospital, were assigned to research groups.Four groups of colorectal normal tissue (n=20),colorectal cancer without liver metastasis(n=20),colorectal cancer with synchronia liver metastasis(n=20),colorectal cancer with heterochronia liver metastasis(n=20) were built up.Correspondence cycle threshold(CT) value of 84 genes expressed in the 80 specimen were analyzed using real-time PCR method based on SYBR green.We compared the expressed quantity between colorectal cancer without liver metastasis and synchronia liver metastasis,colorectal cancer without liver metastasis and heterochronia liver metastasis,synchronia liver metastasis and heterochronia liver metastasis,colorectal normal tissue and colorectal tumor tissue.T test was used to compare the difference among groups, 2~(-△△CT) method was used to analyze the correspondence expressed quantity.
Results:
Four differentially expressed genes were found probably related to colorectal cancer liver metastasis,including three up regulation genes and one down regulation genes.SRC gene is up regulated 2.2 times in colorectal cancer with synchronia liver metastasis(p=0.016),AZGP1 is 2.4 times(p=0.025) up regulated in synchronia liver metastasis,IQCA is 3.5 times(p=0.015) up regulated in synchronia liver metastasis.HCA112 gene is down regulated 0.61 times(p=0.04) in colorectal cancer with heterochronia liver metastasis.
24 differentially expressed genes were found probably related to colorectal cancer.20 genes are down regulated such as EGFL6,HRASLS,HFE, DTX1,SLC16A7,MAF,ST70T1,PLCL2,ISL1,SLC30A7,MAGED4,CAMK2N1,TDGF1, IL28RA,CYP51A1,SCIN,CDKL1,AQP11,GPR160 and CUGBP1,4 genes are up rugulated such as PLEKHH1,SATB2,AP1G2 and MFSD2.
Conclusion"
1) Up regulation of gene SRC,AZGP1 and IQCA in colorectal cancer probably have relationship with colorectal cancer synchronia liver metastasis.
2) Down regulation of gene HCA112 probably have relationship with heterochronia liver metastasis.
3) Down regulation of gene EGFL6,HRASLS,HFE,DTX1,SLC16AT,MAF, STT0T1,PLCL2,ISL1,SLC3OAT,MAGED4,CAMK2N1,TDGF1,IL28RA,CYP51A1, SCIN,CDKL1,AQP11,GPR160 and CUGBP1 may concerned with the development of colorectal cancer.
4) Up regulation of gene PLEKHH1,SATB2,AP1G2 and MFSD2 may concerned with the development of colorectal cancer.
5) All genes need further research.
引文
1 Donald C.McMillan,Colin S.McArdle.Epidemiology of colorectal liver metastases.Surgical Oncology,2007;16:3-5.
2 Khatri VP,Petrelli NJ,Belghiti J.Extending the frontiers of surgical therapy for hepatic colorectal metastases:is there a limit? J Clin Oncol,2005;23:8490-8499.
3 Weber SM,Jamagin WR,De Matteo RP,et al.Survival after resection of multiple hepatic colorectal metastasis.Ann Surg oncol,2000;7(9):643-650.
4 Jatiko GR,Lisbog PH,Stetiner HM,et al.Hepatie reseition for Metatasis from Coloreetal Careinoma-a survival analysis.Eur Cancer,1995;31(A):41
5 Blumgart LH,Fong Y.Surgical options in the treatment of hepatic metastasis for colorectal cancer.Current Problems in Surgery,1995;32(5):337-352.
6 Wilkins M R,Sanchez J C,Gooley a etal.Progress with proteome projects:Why all proteins expressed by genome should be identified and how to do it.Biotech Genet Eng Rev,1995;13:19.
7 Bentrem DJ,DeMatteo RP and Blumgart LH.Surgical therapy for metastatic disease to the liver.Ann RevMed,2005;56:139-156.
8 Poston GJ.Surgical strategies for colorectal liver metastases.Surg Oncol,2004;13:125-36.
9 Takahashi Y.Gastrointestinal cancer.Gan To Kagaku Ryoho,2004;31:1275-1279.
10 Memon MA,Beckingham IJ.Surgical resection of colorectal liver metastases.Colorectal Dis,2001;3(6):361-373.
11 R.Adam.Current surgical strategies for the treatment of colorectal cancer liver metastases.EJC Supplements,2004;2(7):21-26.
12 钦伦秀。肿瘤诊断与预测的分子标记物。见:肿瘤的分子诊断与预测。钦伦秀主编,上海:上海科学教育出版社,2005;3-36。
13 Uner A,Akcali Z and Unsal D.Serum levels of soluble E-selectin in colorectal cancer.Neoplasma,2004;51(4):269-274.
14 Saito T,Masuda N,et al.Expression of EphA2 and E-cadherin in colorectal cancer:correlation with cancer metastasis,Oncol Rep, 2004;(11):605-611.
15 Waas ET,Wobbes T,Pascal DG,et al.Matrix metalloproteinase 2 and 9 activity in patients with colorectal cancer liver metastasis.Br J Surg,2003;90(12):1556-1564.
16 Horiuchi S,Yamamoto H,Min Y,et al.Association of ets-related transcriptional factor E1AF expression with tumour progression and overexpression of MMP-1 and matrilysin in human colorectal cancer.J Pathol.2003;200(5):568-576.
17 Kato H,Semba S,Miskad UA,et al.High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer:a predictive molecular marker of metachronous liver and lung metastases.Clin Cancer Res,2004;10(21):7318-7328.
18 Kenneth J.Livak,Thomas D.Schmittgen.Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2~(-ΔΔCT)Method.METHODS,2001;25:402-408.
19 Lievre A,Bachatte J-B,BligeV,et al.KRAS mutation as an independent prognostic factor in patients with advanced colorectal cancer treated with Cetuximab.J Clin Oncol,2008;26:374-379.
20 Amado IG,Wolf M,Peters M,et al.wild-type KRAS is required for panitunumab efficacy in patients with metastatic colorectal cancer.J Clin Oncol,2008;26:1626-1634.
21 Etienee-Gimeldi M-C,Formenta J-L,Francoual M,et al.KRAS mutation in treatment outcome in colorectal cancer in patients receiving exclusive fluoroyrimidine.Clin Cancer Research,2008;14:4830-4835.
22 Alexander Meyer,Susanne Merkel,Wolfgang Bru¨ ckl,et al.Cdc2 as prognostic marker in stage UICC Ⅱ colon carcinomas.Eur J Cancer(2009),doi:10.1016/j.ejca.2009.01.010.
23 J.S.Nam,Y.Ino,M.Sakamoto,S.Hirohashi,Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis,Clin.Cancer Res,2002;8:2430-2436.
24 Aviaienyte E,FrameMC.Src and FAK signaling controls adhesion fate and the epithelial to mesenchymal transition.CurrOpin Cell Biol, 2005;17(5):542-547.
25 Daniel Sagan,Friederike Eckardt-Schupp,Hedda Eichholtz-Wirth.Reduced expression of SRC family kinases decreases PI3K activity in NBSl-/-Lymphoblasts.Biochemical and Biophysical Research Communications,2008;377:181-186.
26 Clara Grijelmo,Christelle Rodrigue,Magalie Svrcek,et al.Proinvasive activity of BMP-7 through SMAD4/src-independent and ERK/Rac/JNK-dependent signaling pathways in colon cancer cells.Cellular Signalling,2007;19:1722-1732.
27 J ustin M S,Gary E G.Src family kinases in tumor progression and metastasis.Cancer and Metastasis Reviews,2003;22:337-358.
28 Yan Zhao,Maricarmen D.Planas-Silva.Mislocalization of cell-cell adhesion complexes in tamoxifen-resistant breast cancer cells with elevated c-Src tyrosine kinase activity.Cancer Letters,2009;275:204-212.
29 Eun-Jung Park,Hye-Young Min,Hwa-Jin Chung,et al.Down-regulation of c-Src/EGFR-mediated signaling activation is involved in the honokiol-induced cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells.(2009),doi:10.1016/j.canlet.2008.11.029.
30 Jochem,Vijayalakshmi,Marc D.Basson et al.Extracellular pressure stimulates colon cancer cell adhesion in vitro and to surgical wounds by Src(sarcoma protein)activation.The American Journal of Surgery,2004;188:467-473.
31 Komberg LJ.Focal adhesion kinase and its potential involvement in tumor invasion and metastasis.Head Neck,1998;20:745-752.
32 Lark AL,Livasy CA,Calvo B,et al.Overexpression of focal adhesion kinase in primary colorectal carcinomas and colorectal liver metastases:immunohistochemistry and real-time PCR analyses.Clin Cancer Res,2003;9:215-22.
33 Ayaki M,Komatsu K,Mukai M,et al.Reduced expression of focal adhesion kinase in liver metastases compared with matched primary human colorectal adenocarcinomas.Clin Cancer Res,2001;7:3106-3112.
34 P.de Heer,M.M.Koudijs,C.J.H.van de Velde,et al.Combined expression of the non-receptor protein tyrosine kinases FAK and Src in primary colorectal cancer is associated with tumor recurrence and metastasis formation.EJSO,2008;34:1253-1261.
35 Umpleby HC,Fermor B,Symes MO,et al.Viability of exfoliated colorectal carcinoma cells.Br J Surg,1984;71:659-663.
36 Allardyce R,Morreau P,Bagshaw P.Tumor cell distribution following laparoscopic colectomy in a porcine model.Dis Colon Rectum,1996;39:47-52.
37 Vijayalakshmi Thamilselvan,Marcd,Basson.Pressure Activates Colon Cancer Cell Adhesion by Inside-Out Focal Adhesion Complex and Actin Cytoskeletal Signaling.Gastroenterology,2004;126:8-18.
38 Seema Khurana,Sudeep P.George.Regulation of cell structure and function by actin-binding proteins:Villin_s perspective.FEBS Letters,2008;582:2128-2139.
39 Talamonti,M.S.,Roh,M.S.,Curley,S.A.,et al.Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer.J.Clin.Invest,1993;91:53-60.
40 Aligayer,H.,Boyd,D.D.,Heiss,M.M.,et al.Activation of Src kinase in primary colorectal carcinomacarcinoma:an indicator of poor clinical prognosis.Cancer,2002;94:344-351.
41 Stejskal,D;Karpisek,M;Reutova,H,et al.Determination of serum zinc-alpha-2-glycoprotein in patients with metabolic syndrome by a new ELISA.Clinical biochemistry,2008;41:313-316.
42 Hassan,MI;Bilgrami,S;Kumar,V,et al.Crystal Structure of the Novel Complex Formed between Zinc alpha 2-Glycoprotein(ZAG)and Prolactin-Inducible Protein(PIP)from Human Seminal Plasma.J Molecular bio,2008;3(384):663-672.
43 Hale,LP.Zinc alpha-2-glycoprotein regulates melanin production by normal and malignant melanocytes.J Investigative dermatology,2002;2(119):464-470.
44 Lei,G;Arany,I;Tyring,SK,et al.Zinc-alpha(2)-glycoprotein has ribonuclease activity.Archives of biochemistry and biophysics,1998;2(355):160-164.
45 Hassan,MI;Waheed,A;Yadav,S,et al.Zinc alpha 2-glycoprotein:A multidisciplinary protein.Molecular cancer research,2008;6(6):892-906.
46 Russell,ST;Tisdale,MJ.The role of glucocorticoids in the induction of zinc-alpha(2)-glycoprotein expression in adipose tissue in cancer cachexia.British J of cancer,2005;5(92):876-881.
47 He N,Brysk H,Tyring SK,et al.Zinc-alpha(2)-glycoprotein hinders cell proliferation and reduces cdc2 expression.J Cellular Bio,2001;36(suppl):162-169.
48 Bing,C;Bao,Y;Jenkins,J,et al.Zinc-alpha 2-glycoprotein,a lipid mobilizing factor,is expressed in adipocytes and is up-regulated in mice with cancer cachexia.Proceedings of the national academy of sciences of the USA,2004;8(101):2500-2505.
49 Wang Y,Han KJ,Pang XW,et al.Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies.J Immunol,2002;169(2):1102-1109.
50 Nakajima H,Takenaka M,Kaimori JY,et al.Gene expression profile of renal proximal tubules regulated by proteinuria.Kidney Int,2002;61(5):1577-1587.
51 L.Tchakarov,M.-L.Vitale,M.Jeyapragasan,A.Rodriguez Del Castillo,et al.Expression of scinderin,an actin filament-severing protein,in different tissues.FEBS,1990;1(268):209-212.
52 T.Lejen,T.D.Pene,S.D.Rose,J.M.Trifaro,The role of different Scinderin domains in the control of F-actin cytoskeleton during exocytosis,Ann.N.Y.Acad.Sci,2002;971:48-250.
53 J.H.Nedrelow,C.D.Cianci,J.S.Morrow,c-Src binds alpha Ⅱ spectrin's Src homology 3(SH3)domain and blocks calpa insusceptibility by phosphorylating Tyr1176,J.Biol.Chem,2003;278:7735-7741.
54 Seema Khurana,Sudeep P.George.Regulation of cell structure and function by actin-binding proteins:Villin_s perspective.FEBS Letters,2008;582:2128-2139.
55 Liu K,Caldwell SA,Abrams SI.Immune selection and emergence of aggressive tumor variants as negative consequences of Fas-mediated cytotoxicity and altered IFN-gamma-regulated gene expression.Cancer Res,2005;65(10):4376-4388.
56 Shankaran V,Ikeda H,Bruce AT,et al.IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.Nature,2001;410(6832):1107-1111.
57 Soraya Abouzahr,Georges Bismuth,Catherine Gaudin,et al.Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure.PNAS,2006;5(203):1428-1433.
58 Karen W.L.Yee,Susan J.Moore,Michael Midmer et al.NKIAMRE,a novel conserved CDC2-related kinase with features of both mitogen-activated protein kinases and cyclin-dependent kinases.Biochemical and Biophysical Research Communications,2003;308:784-792.
59 Omoji Watanabe,Akio Takagi,Noboru Sasagawa,et al.Altered expression of CUG binding protein 1 mRNA in myotonic dystrophy 1:possible RNA-RNA interaction.Neuroscience Research,2004;49:47-54.
60 imchenko LT,Miller JW,Timchenko NA,et al.Identification of a(CUG)n triplet repeat RNA-binding protein and its expression in myotonic dystrophy.Nucleic Acids Res,1996;24(22):4407-4414.
61 Wang GS,Kearney DL,De Biasi M,et al.Elevation of RNA-binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy.J.Clin.Invest,2007;117(10):2802-2811.
62 Peng SS,Chen CY,Shyu AB.Functional characterization of a non-AUUUA AU-rich element from the c-jun proto-oncogene mRNA:evidence for a novel class of AU-rich elements.Mol.Cell.Biol,1996;16(4):1490-1499.
63 Barreau C,Watrin T,Beverley Osborne H,et al.Protein expression is increased by a class III AU-rich element and tethered CUG-BP1.Biochem.Biophys.Res.Commun,2006;347(3):723-730.
64 Halestrap AP,Meredith D.The SLC16 gene family-from monocarboxylate transporters(MCTs)to aromatic amino acid transporters and beyond. Pflugers Arch,2004;447(5):619-628.
65 Marilyn E.Morris,MelanieA.Felmlee.Overview of the Proton-coupled MCT(SLC16A)Family of Transporters:Characterization,Function and Role in the Transport of the Drug of Abuse γ-Hydroxybutyric Acid.AAPS J.2008;10(2):311-321.
66 Garcia CK,Brown MS,Pathak RK,et al.cDNA cloning of MCT2,a second monocarpboxylate transporter expressed in different cells than MCT1.J.Biol.Chem,1995;270(4):1843-1849.
67 Lin RY,Vera JC,Chaganti RS,et al.Human monocarboxylate transporter 2(MCT2)is a high affinity pyruvate transporter.J.Biol.Chem,1998;273(44):28959-28965.
68 Broer S,Broer A,Schneider HP,Stegen C,et al.Characterization of the highaffinity monocarboxylate transporter MCT2 in Xenopus laevis oocytes.Biochem.J,1999;341:529-535.
69 Yeung G,Mulero JJ,Berntsen RP,Loeb DB,et al.Cloning of a novel epidermal growth factor repeat containing gene EGFL6:expressed in tumor and fetal tissues.Genomics,1999;62(2):304-307.
70 Buchner G,Orfanelli U,Quaderi N,et al.Identification of a new EGF-repeat-containing gene from human Xp22:a candidate for developmental disorders.Genomics,2000;65(1):16-23.
71 Lee SH,Jeong EG,Soung YH,et al.Absence of GNAS and EGFL6 mutations in common human cancers.Pathology,2008;40(1):95-97.
72 Takatsu H,Sakurai M,Shin HW,et al.Identification and characterization of novel clathrin adaptor-related proteins.J.Biol.Chem,1998;273(38):24693-24700.
73 Geyer M,Fackler 0T,Peterlin BM.Structure—function relationships in HIV-1 Nef.EMB0 Rep,2001;2(7):580-585.
74 B(?)nichou S,Benmerah A.The HIV nef and the Kaposi-sarcoma-associated virus K3/K5 proteins:“parasites”of the endocytosis pathway.Med Sci(Paris),2003;19(1):100-6.
75 Ito H,Akiyama H,Shigeno C,et al.Isolation,characterization,and chromosome mapping of a human A-Cl Ha-Ras suppressor gene(HRASLS).Cytogenet Cell Genet,2001;93(1-2):36-39.
76 Akiyama H,Hiraki Y,NodaM,et al..Molecular cloning and biological activity of a novel Ha-Ras suppressor gene predominantly expressed in skeletal muscle,heart,brain,and bone marrow by differential display using clonal mouse EC cells,ATDC5.J Mol Biol,1999;274:32192-32197.
77 Kaneda A,Wakazono K,Tsukamoto T et al.Lysyl oxidase is a tumor suppressor gene inactivated by methylation and loss of heterozygosity in human gastric cancers.Cancer Res,2004;64(18):6410-6415.
78 Mura C,Ragu(?)nes 0,Scotet V,et al.A 6-year survey of HFE gene test for hemochromatosis diagnosis.Genet Med,2005;7(1):68-73.
79 Abraham BK,Justenhoven C,Pesch B,et al.Investigation of genetic variants of genes of the hemochromatosis pathway and their role in breast cancer.Cancer Epidemiol Biomarkers Prev,2005;14(5):1102-1107.
80 McGlynn KA,Sakoda LC,Hu Y,et al.Hemochromatosis gene mutations and distal adenomatous colorectal polyps.Cancer Epidemiol Biomarkers Prev,2005;14(5):1102-1107.
81 R.Colbran,Targeting of calcium/calmodulin-dependent protein kinaseⅡ,Biochem.J,2004;378:1-16.
82 Wang C,Li N,Liu X,et al.A novel endogenous human CaMK Ⅱ inhibitory protein suppresses tumor growth by inducing cell cycle arrest via p27 stabilization.J Biol Chem,2008;283(17):11565-11574.
83 Noriyuki Takai,Tami Ueda,Kaei Nasu,et al.Targeting calcium/calmodulin-dependence kinase Ⅰ and Ⅱ as a potential anti-proliferation remedy for endometrial carcinomas.Cancer Letters,2009;2(277):235-243.
84 Trizzi L,BiancoC,NormannoN,et al.Cripto-1:a multifunctional modulator during embryogenesis and oncogenesis.Oncogene,2005;24:5731-5741.
85 Oaksson K,Zoric N,Zeng X,et al.Monitoring differentiation of human embryonic stem cells using realtime PCR.Stem Cells,2005;23:1460-1467.
86 Normanno N,Bianco C,De Luca A,et al.The role of EGF-related peptides in tumor growth.Front Biosci,2001;6:D685-D657.
87 Minchiotti G.Nodal-dependant Cripto signaling in ES cells:from stem cells to tumor biology.Oncogene,2005;24:5668-5675.
88 De LucaA,Arra C,AntonioA,et al.Simultaneous blockage of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts.Oncogene,2000;19:5863-5871.
89 X-Y Zhong,L-H Zhang,S-Q Jia,et al.Positive association of up-regulated Cripto-1 and down-regulated E-cadherin with tumour progression and poor prognosis in gastric cancer.Histopathology,2008;5.(52):560-568.
90 Caterina Bianco,Luigi Strizzi,MarioMancino,et al.Identification of Cripto-1 as a Novel Serologic Marker for Breast and Colon Cancer.Clin Cancer Res,2006;12(17):5158-5164.
91 Lars Hansen,Hans Eiberg,Thomas Rosenberg.Novel MAF mutation in a family with congenital cataractmicrocornea syndrome.Molecular Vision,2007;13:2019-2022.
92 Joachim Kienast,Wolfgang E.Berdel.c-maf in multiple myeloma:An oncogene enhancing tumor-stroma Interactions.Cancer cell,2004;2:109-110.
93 Esnault C,Priet S,Ribet D,et al.A placenta-specific receptor for the fusogenic,endogenous retrovirus-derived,human syncytin-2.Proc Natl Acad Sci U S A,2008;105(45):17532-17537.
94 Sasaki M,Nakahira K,Kawano Y,et al.a new member of the melanoma-associated antigen gene family and its expression in human glioma.Cancer Res,2001;61(12):4809-4814.
95 Chae SC,Park YR,Li CS,et al.Analysis of the variations in IL-28RA gene and their association with allergic rhinitis.Exp Mol Med,2006;38(3):302-309.
96 Dumoutier L,Lejeune D,Hor S,et al.Cloning of a new type Ⅱ cytokine receptor activating signal transducer and activator of transcription(STAT)l,STAT2 and STAT3.Biochem J,2003;370(Pt 2):391-396.
97 Gorelick DA,Praetorius J,Tsunenari T,et al.Aquaporin-11:a channel protein lacking apparent transport function expressed in brain.BMC Biochem,2006;7:14.
98 Morishita Y,Matsuzaki T,Hara-chikuma M,et al.Disruption of aquaporin-11 produces polycystic kidneys following vacuolization of the proximal tubule.Mol Cell Biol,2005;25(17):7770-7779.
99 Peng SY,Wang WP,Meng J,et al.ISLl physically interacts with BETA2 to promote insulin gene transcriptional synergy in non-beta cells.Biochim.Biophys.Acta,2006;1731(3):154-159.
100 Kirschke CP,Huang L.ZnT7,a novel mammalian zinc transporter,accumulates zinc in the Golgi apparatus.J Biol Chem,2003;278(6):4096-4102.
101 Zhang LH,Wang X,Stoltenberg M,et al.Abundant expression of zinc transporters in the amyloid plaques of Alzheimer' s disease brain.Brain Res Bull,2008;77(1):55-60.
102 Vieira AR,Avila JR,Daack-Hirsch S,et al.Medical sequencing of candidate genes for nonsyndromic cleft lip and palate.PLoS Genet,2005;1(6):e64.
103 FitzPatrick DR,Carr IM,McLaren L,et al.Identification of SATB2 as the cleft palate gene on 2q32-q33.Hum Mol Genet,2003;12(19):2491-2501.
104 Lee L,Dowhanick-Morrissette J,Katz A,et al.Chromosomal localization,genomic characterization,and mapping to the Noonan syndrome critical region of the human Deltex(DTX1)gene.Hum Genet,2000;107(6):577-581.
105 Vincent JB,Petek E,Thevarkunnel S,et al.The RAY1/ST7 tumor-suppressor locus on chromosome 7q31 represents a complex multi-transcript system.Genomics,2002;80(3):283-294.
1 Donald C.McMillan,Colin S.McArdle.Epidemiology of colorectal liver metastases.Surgical Oncology,2007:16:3-5.
2 Khatri VP,Petrelli NJ,Belghiti J.Extending the frontiers of surgical therapy for hepatic colorectal metastases:is there a limit?J Clin Oncol,2005;23:8490-9.
3 Maruyama K,Tanaka T,et al.p53 accumulation in colorectal cancer with hepatic metastasis.Japanese J Cancer research,1996;87:368-376.
4 Kern A,Taubert H,Scheele J,et al.Association of p53 mutation,microvessel density and neoangiogenesis in pairs of colorectal cancers and corresponding liver metastasis.Int J Oncol,2002,;21(2):243-249.
5 Tachibana M,Kawamata H,Fujimori T,et al.Dysfunction of p53 pathway in human colorectal cancer:analysis of p53 gene mutation and the expression of the p53-associated factors p14ARF,p33ING1,p21WAF1 and MDM2.Int J Oncol,2004;25(4):913-920.
6 王晓玫,陶凤华,成志强,等。结直肠癌MDM2基因表达与生物学行为的关系。第四军医大学学报,2003;24(15):1356-8。
7 Li JQ,Miki H,et al.Expression of cyclin E and cyclin-dependent kinase 2 correlates with metastasis and prognosis in colorectal carcinoma.Rum Pathol,2001;32(9):945-53.
8 Rodel F,Roffmann J,Grabenbauer GG,et al.High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection.Strahlenther Onkol,2002;178(8):426-35.
9 杨景,柳凤轩,阎晓初,等。Survivin在结直肠癌组织中表达的临床意义及其与细胞凋亡、血管生成的关系。癌症,2005;24(1):116-120。
10 Pyrko,P.,Soriano,N.,Kardosh,A.,et al.Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog,dimethyl-celecoxib (DMC),in tumor cells in vitro and in vivo.Mot.Cancer,2006;5:19.
11 Po-Wen Hsiao,Chia-Ching Chang,Huei-Fang Liu et al.Activation of p38 mitogen-activated protein kinase by celecoxib oppositely regulates survivin and gamma-H2AX in human colorectal cancer cells.Toxicology and Applied Pharmacology,2007:222(1):97-104.
12 Chew Yee Ngan,Hirofumi Yamamoto,Iwao Seshimo,et al.A multivariate analysis of adhesion molecules expression in assessment of colorectal cancer.Journal of Surgical Oncology,2007;95(8):652-662.
13 Akiko Tachimori,Nobuya Yamada,Yoji Sakate,et al.Up regulation of ICAM-1 gene expression inhibits tumour growth and liver metastasis in colorectal carcinoma.European Journal of Cancer,2005:41:1802-1810.
14 S.A.Han,H..Chun,C.M.Park,et al.Prognostic Significance of b-catenin in Colorectal Cancer with Liver Metastasis.Clinical Oncology,2006;18:761-767.
15 Hanrahan V,Currie MJ,Gunningham SP,et al.The angiogenic switch for vascular endothelial growth factor(VEGF)-A,VEGF-B,VEGF-C,and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.J Pathol,2003;200:183-194.
16 Sarah E.Duff,Maria Jeziorska,Daniela D.Rosa,et al.Vascular endothelial growth factors and receptors in colorectal cancer:Implications for anti-angiogenic therapy.European Journal of Cancer,2006;42:112-117.
17 Ferrara N.Vascular endothelial growth factor:basic science and clinical progress.Endocr Rev,2004;4:581-611.
18 Steele RJ,Kelly P,Ellul B,et al.Epidermal growth factor receptor expression in colorectal cancer.Br J Surg,1990;77(12):1352-4.
19 Kimmie Ng,Andrew X.Zhu.Targeting the epidermal growth factor receptor in metastatic colorectal cancer.Critical Reviews in Oncology/Hematology,2008;65(1):8-20.
20 Fazekas K,Csuka O,Koves I,et al.experimental and clinicopathologic studies on the function of the HGF receptor in human colon cancer metastasis.Clin Exp Metastasis,2000;18:639-649.
21 韦烨,许剑民,卢雪一,等。C-met protoncogene在结直肠癌肝转移诊断。中的应用。中国癌症杂志,2006;12(16):993-997。
22 E.A.Baker,D.J.Leaper.The plasminogen activator and matrix metalloproteinase systems in colorectal cancer:relationship to tumour pathology.European Journal of Cancer,2003;39:981-988.
23 Toshimichi Asano,Mitsuhiro Tada,Shaoqiang Cheng,et al.Prognostic Values of Matrix Metalloproteinase Family Expression in Human Colorectal Carcinoma.Journal of Surgical Research,In Press,Available online 31 May 2007.
24 Lars Frich,,Kristin Bj(?)rnland,Solveig Pettersen,et al.Increased Activity of Matrix Metalloproteinase 2 and 9 After Hepatic Radiofrequency Ablation.Journal of Surgical Research,2006;135:297-304.
25 Ishida H,Sadahiro S,et al.c-erbB-2 protein expression and clinicopathologic features in colorectal cancer.Oncol Rep,2000;7:1229-33.
26 Christos Tsigrisa,Anastasios J.Karayiannakis,Andrew Zbar,et al.Clinical significance of serum and urinary c-erbB-2 levels in colorectal cancer.Cancer Letters,2002;184:215-222.
27 Nikolaus Ansorge,Stefan J(?)ttner,Thorsten Cramer,et al.An upstream CRE-E-box element is essential for gastrin-dependent activation of the cyclooxygenase-2 gene in human colon cancer cells.Regulatory Peptides,2007;144:25-33.
28 TomozawaS,TsunoNH,Sunami E,et al.Cyclooxygenase-2 overexpression correlates with tumour recurrence,esprcially haematogenous metastasis,of colorectal cancer.Br J Cancer,2000;83:324-328.
29 Jin C.Kim,Seon A.Roh,Hee C.Kim,et al.Coexpression of Carcinoembryonic Antigen and E-cadherin in Colorectal Adenocarcinoma With Liver Metastasis.Journal of Gastrointestinal Surgery,2003;7:931-938.
30 Berney,Christophe R,Fisher,Richard J,Yang,Jia-lin,et al.Protein Markers in Colorectal Cancer:Predictors of Liver Metastasis.Annals of Surgery,1999;230(2):179-84.
31 Ohue M.Takahashi K.Yamaguchi T.et al.High concentration of E-cadherin in portal drainage vein of colorectal cancer patients may predict metachronous liver metastasis.Japanese Journal of Cancer & Chemotherapy,2002;29(12):2263-6.
32 Yasuo Takahashi,Yukimoto Ishii,Yayoi Nishida,et al.Detection of aberrations of ubiquitin-conjugating enzyme E2C gene(UBE2C)in advanced colon cancer with liver metastases by DNA microarray and two-color FISH.Cancer Genetics and Cytogenetics,2006;168:30-35.
33 Jinhua Wen,Kunio Matsumoto,Naoko Taniura,et al.Inhibition of colon cancer growth and metastasis by NK4 gene repetitive delivery in mice.Biochemical and Biophysical Research Communications,2007;358:117-123.
34 Michiaki Ishii,Masaki Iwai,Yoshinori Harada,et al.Soluble TRAIL gene and actinomycin D synergistically suppressed multiple metastasis of TRAIL-resistant colon cancer in the liver.Cancer Letters,2007;245:134-143.
35 Anja H.Wiese,Johannes Auer,Silke Lassmann,et al.Identification of gene signatures for invasive colorectal tumor cells.Cancer Detection and Prevention,2007;31:282-295.
2 Khatri VP,Petrelli NJ,Belghiti J.Extending the frontiers of surgical therapy for hepatic colorectal metastases:is there a limit? J Clin Oncol,2005;23:8490-8499.
3 Weber SM,Jamagin WR,De Matteo RP,et al.Survival after resection of multiple hepatic colorectal metastasis.Ann Surg oncol,2000;7(9):643-650.
4 Jatiko GR,Lisbog PH,Stetiner HM,et al.Hepatie reseition for Metatasis from Coloreetal Careinoma-a survival analysis.Eur Cancer,1995;31(A):41
5 Blumgart LH,Fong Y.Surgical options in the treatment of hepatic metastasis for colorectal cancer.Current Problems in Surgery,1995;32(5):337-352.
6 Wilkins M R,Sanchez J C,Gooley a etal.Progress with proteome projects:Why all proteins expressed by genome should be identified and how to do it.Biotech Genet Eng Rev,1995;13:19.
7 Bentrem DJ,DeMatteo RP and Blumgart LH.Surgical therapy for metastatic disease to the liver.Ann RevMed,2005;56:139-156.
8 Poston GJ.Surgical strategies for colorectal liver metastases.Surg Oncol,2004;13:125-36.
9 Takahashi Y.Gastrointestinal cancer.Gan To Kagaku Ryoho,2004;31:1275-1279.
10 Memon MA,Beckingham IJ.Surgical resection of colorectal liver metastases.Colorectal Dis,2001;3(6):361-373.
11 R.Adam.Current surgical strategies for the treatment of colorectal cancer liver metastases.EJC Supplements,2004;2(7):21-26.
12 钦伦秀。肿瘤诊断与预测的分子标记物。见:肿瘤的分子诊断与预测。钦伦秀主编,上海:上海科学教育出版社,2005;3-36。
13 Uner A,Akcali Z and Unsal D.Serum levels of soluble E-selectin in colorectal cancer.Neoplasma,2004;51(4):269-274.
14 Saito T,Masuda N,et al.Expression of EphA2 and E-cadherin in colorectal cancer:correlation with cancer metastasis,Oncol Rep, 2004;(11):605-611.
15 Waas ET,Wobbes T,Pascal DG,et al.Matrix metalloproteinase 2 and 9 activity in patients with colorectal cancer liver metastasis.Br J Surg,2003;90(12):1556-1564.
16 Horiuchi S,Yamamoto H,Min Y,et al.Association of ets-related transcriptional factor E1AF expression with tumour progression and overexpression of MMP-1 and matrilysin in human colorectal cancer.J Pathol.2003;200(5):568-576.
17 Kato H,Semba S,Miskad UA,et al.High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer:a predictive molecular marker of metachronous liver and lung metastases.Clin Cancer Res,2004;10(21):7318-7328.
18 Kenneth J.Livak,Thomas D.Schmittgen.Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2~(-ΔΔCT)Method.METHODS,2001;25:402-408.
19 Lievre A,Bachatte J-B,BligeV,et al.KRAS mutation as an independent prognostic factor in patients with advanced colorectal cancer treated with Cetuximab.J Clin Oncol,2008;26:374-379.
20 Amado IG,Wolf M,Peters M,et al.wild-type KRAS is required for panitunumab efficacy in patients with metastatic colorectal cancer.J Clin Oncol,2008;26:1626-1634.
21 Etienee-Gimeldi M-C,Formenta J-L,Francoual M,et al.KRAS mutation in treatment outcome in colorectal cancer in patients receiving exclusive fluoroyrimidine.Clin Cancer Research,2008;14:4830-4835.
22 Alexander Meyer,Susanne Merkel,Wolfgang Bru¨ ckl,et al.Cdc2 as prognostic marker in stage UICC Ⅱ colon carcinomas.Eur J Cancer(2009),doi:10.1016/j.ejca.2009.01.010.
23 J.S.Nam,Y.Ino,M.Sakamoto,S.Hirohashi,Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis,Clin.Cancer Res,2002;8:2430-2436.
24 Aviaienyte E,FrameMC.Src and FAK signaling controls adhesion fate and the epithelial to mesenchymal transition.CurrOpin Cell Biol, 2005;17(5):542-547.
25 Daniel Sagan,Friederike Eckardt-Schupp,Hedda Eichholtz-Wirth.Reduced expression of SRC family kinases decreases PI3K activity in NBSl-/-Lymphoblasts.Biochemical and Biophysical Research Communications,2008;377:181-186.
26 Clara Grijelmo,Christelle Rodrigue,Magalie Svrcek,et al.Proinvasive activity of BMP-7 through SMAD4/src-independent and ERK/Rac/JNK-dependent signaling pathways in colon cancer cells.Cellular Signalling,2007;19:1722-1732.
27 J ustin M S,Gary E G.Src family kinases in tumor progression and metastasis.Cancer and Metastasis Reviews,2003;22:337-358.
28 Yan Zhao,Maricarmen D.Planas-Silva.Mislocalization of cell-cell adhesion complexes in tamoxifen-resistant breast cancer cells with elevated c-Src tyrosine kinase activity.Cancer Letters,2009;275:204-212.
29 Eun-Jung Park,Hye-Young Min,Hwa-Jin Chung,et al.Down-regulation of c-Src/EGFR-mediated signaling activation is involved in the honokiol-induced cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells.(2009),doi:10.1016/j.canlet.2008.11.029.
30 Jochem,Vijayalakshmi,Marc D.Basson et al.Extracellular pressure stimulates colon cancer cell adhesion in vitro and to surgical wounds by Src(sarcoma protein)activation.The American Journal of Surgery,2004;188:467-473.
31 Komberg LJ.Focal adhesion kinase and its potential involvement in tumor invasion and metastasis.Head Neck,1998;20:745-752.
32 Lark AL,Livasy CA,Calvo B,et al.Overexpression of focal adhesion kinase in primary colorectal carcinomas and colorectal liver metastases:immunohistochemistry and real-time PCR analyses.Clin Cancer Res,2003;9:215-22.
33 Ayaki M,Komatsu K,Mukai M,et al.Reduced expression of focal adhesion kinase in liver metastases compared with matched primary human colorectal adenocarcinomas.Clin Cancer Res,2001;7:3106-3112.
34 P.de Heer,M.M.Koudijs,C.J.H.van de Velde,et al.Combined expression of the non-receptor protein tyrosine kinases FAK and Src in primary colorectal cancer is associated with tumor recurrence and metastasis formation.EJSO,2008;34:1253-1261.
35 Umpleby HC,Fermor B,Symes MO,et al.Viability of exfoliated colorectal carcinoma cells.Br J Surg,1984;71:659-663.
36 Allardyce R,Morreau P,Bagshaw P.Tumor cell distribution following laparoscopic colectomy in a porcine model.Dis Colon Rectum,1996;39:47-52.
37 Vijayalakshmi Thamilselvan,Marcd,Basson.Pressure Activates Colon Cancer Cell Adhesion by Inside-Out Focal Adhesion Complex and Actin Cytoskeletal Signaling.Gastroenterology,2004;126:8-18.
38 Seema Khurana,Sudeep P.George.Regulation of cell structure and function by actin-binding proteins:Villin_s perspective.FEBS Letters,2008;582:2128-2139.
39 Talamonti,M.S.,Roh,M.S.,Curley,S.A.,et al.Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer.J.Clin.Invest,1993;91:53-60.
40 Aligayer,H.,Boyd,D.D.,Heiss,M.M.,et al.Activation of Src kinase in primary colorectal carcinomacarcinoma:an indicator of poor clinical prognosis.Cancer,2002;94:344-351.
41 Stejskal,D;Karpisek,M;Reutova,H,et al.Determination of serum zinc-alpha-2-glycoprotein in patients with metabolic syndrome by a new ELISA.Clinical biochemistry,2008;41:313-316.
42 Hassan,MI;Bilgrami,S;Kumar,V,et al.Crystal Structure of the Novel Complex Formed between Zinc alpha 2-Glycoprotein(ZAG)and Prolactin-Inducible Protein(PIP)from Human Seminal Plasma.J Molecular bio,2008;3(384):663-672.
43 Hale,LP.Zinc alpha-2-glycoprotein regulates melanin production by normal and malignant melanocytes.J Investigative dermatology,2002;2(119):464-470.
44 Lei,G;Arany,I;Tyring,SK,et al.Zinc-alpha(2)-glycoprotein has ribonuclease activity.Archives of biochemistry and biophysics,1998;2(355):160-164.
45 Hassan,MI;Waheed,A;Yadav,S,et al.Zinc alpha 2-glycoprotein:A multidisciplinary protein.Molecular cancer research,2008;6(6):892-906.
46 Russell,ST;Tisdale,MJ.The role of glucocorticoids in the induction of zinc-alpha(2)-glycoprotein expression in adipose tissue in cancer cachexia.British J of cancer,2005;5(92):876-881.
47 He N,Brysk H,Tyring SK,et al.Zinc-alpha(2)-glycoprotein hinders cell proliferation and reduces cdc2 expression.J Cellular Bio,2001;36(suppl):162-169.
48 Bing,C;Bao,Y;Jenkins,J,et al.Zinc-alpha 2-glycoprotein,a lipid mobilizing factor,is expressed in adipocytes and is up-regulated in mice with cancer cachexia.Proceedings of the national academy of sciences of the USA,2004;8(101):2500-2505.
49 Wang Y,Han KJ,Pang XW,et al.Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies.J Immunol,2002;169(2):1102-1109.
50 Nakajima H,Takenaka M,Kaimori JY,et al.Gene expression profile of renal proximal tubules regulated by proteinuria.Kidney Int,2002;61(5):1577-1587.
51 L.Tchakarov,M.-L.Vitale,M.Jeyapragasan,A.Rodriguez Del Castillo,et al.Expression of scinderin,an actin filament-severing protein,in different tissues.FEBS,1990;1(268):209-212.
52 T.Lejen,T.D.Pene,S.D.Rose,J.M.Trifaro,The role of different Scinderin domains in the control of F-actin cytoskeleton during exocytosis,Ann.N.Y.Acad.Sci,2002;971:48-250.
53 J.H.Nedrelow,C.D.Cianci,J.S.Morrow,c-Src binds alpha Ⅱ spectrin's Src homology 3(SH3)domain and blocks calpa insusceptibility by phosphorylating Tyr1176,J.Biol.Chem,2003;278:7735-7741.
54 Seema Khurana,Sudeep P.George.Regulation of cell structure and function by actin-binding proteins:Villin_s perspective.FEBS Letters,2008;582:2128-2139.
55 Liu K,Caldwell SA,Abrams SI.Immune selection and emergence of aggressive tumor variants as negative consequences of Fas-mediated cytotoxicity and altered IFN-gamma-regulated gene expression.Cancer Res,2005;65(10):4376-4388.
56 Shankaran V,Ikeda H,Bruce AT,et al.IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.Nature,2001;410(6832):1107-1111.
57 Soraya Abouzahr,Georges Bismuth,Catherine Gaudin,et al.Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure.PNAS,2006;5(203):1428-1433.
58 Karen W.L.Yee,Susan J.Moore,Michael Midmer et al.NKIAMRE,a novel conserved CDC2-related kinase with features of both mitogen-activated protein kinases and cyclin-dependent kinases.Biochemical and Biophysical Research Communications,2003;308:784-792.
59 Omoji Watanabe,Akio Takagi,Noboru Sasagawa,et al.Altered expression of CUG binding protein 1 mRNA in myotonic dystrophy 1:possible RNA-RNA interaction.Neuroscience Research,2004;49:47-54.
60 imchenko LT,Miller JW,Timchenko NA,et al.Identification of a(CUG)n triplet repeat RNA-binding protein and its expression in myotonic dystrophy.Nucleic Acids Res,1996;24(22):4407-4414.
61 Wang GS,Kearney DL,De Biasi M,et al.Elevation of RNA-binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy.J.Clin.Invest,2007;117(10):2802-2811.
62 Peng SS,Chen CY,Shyu AB.Functional characterization of a non-AUUUA AU-rich element from the c-jun proto-oncogene mRNA:evidence for a novel class of AU-rich elements.Mol.Cell.Biol,1996;16(4):1490-1499.
63 Barreau C,Watrin T,Beverley Osborne H,et al.Protein expression is increased by a class III AU-rich element and tethered CUG-BP1.Biochem.Biophys.Res.Commun,2006;347(3):723-730.
64 Halestrap AP,Meredith D.The SLC16 gene family-from monocarboxylate transporters(MCTs)to aromatic amino acid transporters and beyond. Pflugers Arch,2004;447(5):619-628.
65 Marilyn E.Morris,MelanieA.Felmlee.Overview of the Proton-coupled MCT(SLC16A)Family of Transporters:Characterization,Function and Role in the Transport of the Drug of Abuse γ-Hydroxybutyric Acid.AAPS J.2008;10(2):311-321.
66 Garcia CK,Brown MS,Pathak RK,et al.cDNA cloning of MCT2,a second monocarpboxylate transporter expressed in different cells than MCT1.J.Biol.Chem,1995;270(4):1843-1849.
67 Lin RY,Vera JC,Chaganti RS,et al.Human monocarboxylate transporter 2(MCT2)is a high affinity pyruvate transporter.J.Biol.Chem,1998;273(44):28959-28965.
68 Broer S,Broer A,Schneider HP,Stegen C,et al.Characterization of the highaffinity monocarboxylate transporter MCT2 in Xenopus laevis oocytes.Biochem.J,1999;341:529-535.
69 Yeung G,Mulero JJ,Berntsen RP,Loeb DB,et al.Cloning of a novel epidermal growth factor repeat containing gene EGFL6:expressed in tumor and fetal tissues.Genomics,1999;62(2):304-307.
70 Buchner G,Orfanelli U,Quaderi N,et al.Identification of a new EGF-repeat-containing gene from human Xp22:a candidate for developmental disorders.Genomics,2000;65(1):16-23.
71 Lee SH,Jeong EG,Soung YH,et al.Absence of GNAS and EGFL6 mutations in common human cancers.Pathology,2008;40(1):95-97.
72 Takatsu H,Sakurai M,Shin HW,et al.Identification and characterization of novel clathrin adaptor-related proteins.J.Biol.Chem,1998;273(38):24693-24700.
73 Geyer M,Fackler 0T,Peterlin BM.Structure—function relationships in HIV-1 Nef.EMB0 Rep,2001;2(7):580-585.
74 B(?)nichou S,Benmerah A.The HIV nef and the Kaposi-sarcoma-associated virus K3/K5 proteins:“parasites”of the endocytosis pathway.Med Sci(Paris),2003;19(1):100-6.
75 Ito H,Akiyama H,Shigeno C,et al.Isolation,characterization,and chromosome mapping of a human A-Cl Ha-Ras suppressor gene(HRASLS).Cytogenet Cell Genet,2001;93(1-2):36-39.
76 Akiyama H,Hiraki Y,NodaM,et al..Molecular cloning and biological activity of a novel Ha-Ras suppressor gene predominantly expressed in skeletal muscle,heart,brain,and bone marrow by differential display using clonal mouse EC cells,ATDC5.J Mol Biol,1999;274:32192-32197.
77 Kaneda A,Wakazono K,Tsukamoto T et al.Lysyl oxidase is a tumor suppressor gene inactivated by methylation and loss of heterozygosity in human gastric cancers.Cancer Res,2004;64(18):6410-6415.
78 Mura C,Ragu(?)nes 0,Scotet V,et al.A 6-year survey of HFE gene test for hemochromatosis diagnosis.Genet Med,2005;7(1):68-73.
79 Abraham BK,Justenhoven C,Pesch B,et al.Investigation of genetic variants of genes of the hemochromatosis pathway and their role in breast cancer.Cancer Epidemiol Biomarkers Prev,2005;14(5):1102-1107.
80 McGlynn KA,Sakoda LC,Hu Y,et al.Hemochromatosis gene mutations and distal adenomatous colorectal polyps.Cancer Epidemiol Biomarkers Prev,2005;14(5):1102-1107.
81 R.Colbran,Targeting of calcium/calmodulin-dependent protein kinaseⅡ,Biochem.J,2004;378:1-16.
82 Wang C,Li N,Liu X,et al.A novel endogenous human CaMK Ⅱ inhibitory protein suppresses tumor growth by inducing cell cycle arrest via p27 stabilization.J Biol Chem,2008;283(17):11565-11574.
83 Noriyuki Takai,Tami Ueda,Kaei Nasu,et al.Targeting calcium/calmodulin-dependence kinase Ⅰ and Ⅱ as a potential anti-proliferation remedy for endometrial carcinomas.Cancer Letters,2009;2(277):235-243.
84 Trizzi L,BiancoC,NormannoN,et al.Cripto-1:a multifunctional modulator during embryogenesis and oncogenesis.Oncogene,2005;24:5731-5741.
85 Oaksson K,Zoric N,Zeng X,et al.Monitoring differentiation of human embryonic stem cells using realtime PCR.Stem Cells,2005;23:1460-1467.
86 Normanno N,Bianco C,De Luca A,et al.The role of EGF-related peptides in tumor growth.Front Biosci,2001;6:D685-D657.
87 Minchiotti G.Nodal-dependant Cripto signaling in ES cells:from stem cells to tumor biology.Oncogene,2005;24:5668-5675.
88 De LucaA,Arra C,AntonioA,et al.Simultaneous blockage of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts.Oncogene,2000;19:5863-5871.
89 X-Y Zhong,L-H Zhang,S-Q Jia,et al.Positive association of up-regulated Cripto-1 and down-regulated E-cadherin with tumour progression and poor prognosis in gastric cancer.Histopathology,2008;5.(52):560-568.
90 Caterina Bianco,Luigi Strizzi,MarioMancino,et al.Identification of Cripto-1 as a Novel Serologic Marker for Breast and Colon Cancer.Clin Cancer Res,2006;12(17):5158-5164.
91 Lars Hansen,Hans Eiberg,Thomas Rosenberg.Novel MAF mutation in a family with congenital cataractmicrocornea syndrome.Molecular Vision,2007;13:2019-2022.
92 Joachim Kienast,Wolfgang E.Berdel.c-maf in multiple myeloma:An oncogene enhancing tumor-stroma Interactions.Cancer cell,2004;2:109-110.
93 Esnault C,Priet S,Ribet D,et al.A placenta-specific receptor for the fusogenic,endogenous retrovirus-derived,human syncytin-2.Proc Natl Acad Sci U S A,2008;105(45):17532-17537.
94 Sasaki M,Nakahira K,Kawano Y,et al.a new member of the melanoma-associated antigen gene family and its expression in human glioma.Cancer Res,2001;61(12):4809-4814.
95 Chae SC,Park YR,Li CS,et al.Analysis of the variations in IL-28RA gene and their association with allergic rhinitis.Exp Mol Med,2006;38(3):302-309.
96 Dumoutier L,Lejeune D,Hor S,et al.Cloning of a new type Ⅱ cytokine receptor activating signal transducer and activator of transcription(STAT)l,STAT2 and STAT3.Biochem J,2003;370(Pt 2):391-396.
97 Gorelick DA,Praetorius J,Tsunenari T,et al.Aquaporin-11:a channel protein lacking apparent transport function expressed in brain.BMC Biochem,2006;7:14.
98 Morishita Y,Matsuzaki T,Hara-chikuma M,et al.Disruption of aquaporin-11 produces polycystic kidneys following vacuolization of the proximal tubule.Mol Cell Biol,2005;25(17):7770-7779.
99 Peng SY,Wang WP,Meng J,et al.ISLl physically interacts with BETA2 to promote insulin gene transcriptional synergy in non-beta cells.Biochim.Biophys.Acta,2006;1731(3):154-159.
100 Kirschke CP,Huang L.ZnT7,a novel mammalian zinc transporter,accumulates zinc in the Golgi apparatus.J Biol Chem,2003;278(6):4096-4102.
101 Zhang LH,Wang X,Stoltenberg M,et al.Abundant expression of zinc transporters in the amyloid plaques of Alzheimer' s disease brain.Brain Res Bull,2008;77(1):55-60.
102 Vieira AR,Avila JR,Daack-Hirsch S,et al.Medical sequencing of candidate genes for nonsyndromic cleft lip and palate.PLoS Genet,2005;1(6):e64.
103 FitzPatrick DR,Carr IM,McLaren L,et al.Identification of SATB2 as the cleft palate gene on 2q32-q33.Hum Mol Genet,2003;12(19):2491-2501.
104 Lee L,Dowhanick-Morrissette J,Katz A,et al.Chromosomal localization,genomic characterization,and mapping to the Noonan syndrome critical region of the human Deltex(DTX1)gene.Hum Genet,2000;107(6):577-581.
105 Vincent JB,Petek E,Thevarkunnel S,et al.The RAY1/ST7 tumor-suppressor locus on chromosome 7q31 represents a complex multi-transcript system.Genomics,2002;80(3):283-294.
1 Donald C.McMillan,Colin S.McArdle.Epidemiology of colorectal liver metastases.Surgical Oncology,2007:16:3-5.
2 Khatri VP,Petrelli NJ,Belghiti J.Extending the frontiers of surgical therapy for hepatic colorectal metastases:is there a limit?J Clin Oncol,2005;23:8490-9.
3 Maruyama K,Tanaka T,et al.p53 accumulation in colorectal cancer with hepatic metastasis.Japanese J Cancer research,1996;87:368-376.
4 Kern A,Taubert H,Scheele J,et al.Association of p53 mutation,microvessel density and neoangiogenesis in pairs of colorectal cancers and corresponding liver metastasis.Int J Oncol,2002,;21(2):243-249.
5 Tachibana M,Kawamata H,Fujimori T,et al.Dysfunction of p53 pathway in human colorectal cancer:analysis of p53 gene mutation and the expression of the p53-associated factors p14ARF,p33ING1,p21WAF1 and MDM2.Int J Oncol,2004;25(4):913-920.
6 王晓玫,陶凤华,成志强,等。结直肠癌MDM2基因表达与生物学行为的关系。第四军医大学学报,2003;24(15):1356-8。
7 Li JQ,Miki H,et al.Expression of cyclin E and cyclin-dependent kinase 2 correlates with metastasis and prognosis in colorectal carcinoma.Rum Pathol,2001;32(9):945-53.
8 Rodel F,Roffmann J,Grabenbauer GG,et al.High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection.Strahlenther Onkol,2002;178(8):426-35.
9 杨景,柳凤轩,阎晓初,等。Survivin在结直肠癌组织中表达的临床意义及其与细胞凋亡、血管生成的关系。癌症,2005;24(1):116-120。
10 Pyrko,P.,Soriano,N.,Kardosh,A.,et al.Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog,dimethyl-celecoxib (DMC),in tumor cells in vitro and in vivo.Mot.Cancer,2006;5:19.
11 Po-Wen Hsiao,Chia-Ching Chang,Huei-Fang Liu et al.Activation of p38 mitogen-activated protein kinase by celecoxib oppositely regulates survivin and gamma-H2AX in human colorectal cancer cells.Toxicology and Applied Pharmacology,2007:222(1):97-104.
12 Chew Yee Ngan,Hirofumi Yamamoto,Iwao Seshimo,et al.A multivariate analysis of adhesion molecules expression in assessment of colorectal cancer.Journal of Surgical Oncology,2007;95(8):652-662.
13 Akiko Tachimori,Nobuya Yamada,Yoji Sakate,et al.Up regulation of ICAM-1 gene expression inhibits tumour growth and liver metastasis in colorectal carcinoma.European Journal of Cancer,2005:41:1802-1810.
14 S.A.Han,H..Chun,C.M.Park,et al.Prognostic Significance of b-catenin in Colorectal Cancer with Liver Metastasis.Clinical Oncology,2006;18:761-767.
15 Hanrahan V,Currie MJ,Gunningham SP,et al.The angiogenic switch for vascular endothelial growth factor(VEGF)-A,VEGF-B,VEGF-C,and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.J Pathol,2003;200:183-194.
16 Sarah E.Duff,Maria Jeziorska,Daniela D.Rosa,et al.Vascular endothelial growth factors and receptors in colorectal cancer:Implications for anti-angiogenic therapy.European Journal of Cancer,2006;42:112-117.
17 Ferrara N.Vascular endothelial growth factor:basic science and clinical progress.Endocr Rev,2004;4:581-611.
18 Steele RJ,Kelly P,Ellul B,et al.Epidermal growth factor receptor expression in colorectal cancer.Br J Surg,1990;77(12):1352-4.
19 Kimmie Ng,Andrew X.Zhu.Targeting the epidermal growth factor receptor in metastatic colorectal cancer.Critical Reviews in Oncology/Hematology,2008;65(1):8-20.
20 Fazekas K,Csuka O,Koves I,et al.experimental and clinicopathologic studies on the function of the HGF receptor in human colon cancer metastasis.Clin Exp Metastasis,2000;18:639-649.
21 韦烨,许剑民,卢雪一,等。C-met protoncogene在结直肠癌肝转移诊断。中的应用。中国癌症杂志,2006;12(16):993-997。
22 E.A.Baker,D.J.Leaper.The plasminogen activator and matrix metalloproteinase systems in colorectal cancer:relationship to tumour pathology.European Journal of Cancer,2003;39:981-988.
23 Toshimichi Asano,Mitsuhiro Tada,Shaoqiang Cheng,et al.Prognostic Values of Matrix Metalloproteinase Family Expression in Human Colorectal Carcinoma.Journal of Surgical Research,In Press,Available online 31 May 2007.
24 Lars Frich,,Kristin Bj(?)rnland,Solveig Pettersen,et al.Increased Activity of Matrix Metalloproteinase 2 and 9 After Hepatic Radiofrequency Ablation.Journal of Surgical Research,2006;135:297-304.
25 Ishida H,Sadahiro S,et al.c-erbB-2 protein expression and clinicopathologic features in colorectal cancer.Oncol Rep,2000;7:1229-33.
26 Christos Tsigrisa,Anastasios J.Karayiannakis,Andrew Zbar,et al.Clinical significance of serum and urinary c-erbB-2 levels in colorectal cancer.Cancer Letters,2002;184:215-222.
27 Nikolaus Ansorge,Stefan J(?)ttner,Thorsten Cramer,et al.An upstream CRE-E-box element is essential for gastrin-dependent activation of the cyclooxygenase-2 gene in human colon cancer cells.Regulatory Peptides,2007;144:25-33.
28 TomozawaS,TsunoNH,Sunami E,et al.Cyclooxygenase-2 overexpression correlates with tumour recurrence,esprcially haematogenous metastasis,of colorectal cancer.Br J Cancer,2000;83:324-328.
29 Jin C.Kim,Seon A.Roh,Hee C.Kim,et al.Coexpression of Carcinoembryonic Antigen and E-cadherin in Colorectal Adenocarcinoma With Liver Metastasis.Journal of Gastrointestinal Surgery,2003;7:931-938.
30 Berney,Christophe R,Fisher,Richard J,Yang,Jia-lin,et al.Protein Markers in Colorectal Cancer:Predictors of Liver Metastasis.Annals of Surgery,1999;230(2):179-84.
31 Ohue M.Takahashi K.Yamaguchi T.et al.High concentration of E-cadherin in portal drainage vein of colorectal cancer patients may predict metachronous liver metastasis.Japanese Journal of Cancer & Chemotherapy,2002;29(12):2263-6.
32 Yasuo Takahashi,Yukimoto Ishii,Yayoi Nishida,et al.Detection of aberrations of ubiquitin-conjugating enzyme E2C gene(UBE2C)in advanced colon cancer with liver metastases by DNA microarray and two-color FISH.Cancer Genetics and Cytogenetics,2006;168:30-35.
33 Jinhua Wen,Kunio Matsumoto,Naoko Taniura,et al.Inhibition of colon cancer growth and metastasis by NK4 gene repetitive delivery in mice.Biochemical and Biophysical Research Communications,2007;358:117-123.
34 Michiaki Ishii,Masaki Iwai,Yoshinori Harada,et al.Soluble TRAIL gene and actinomycin D synergistically suppressed multiple metastasis of TRAIL-resistant colon cancer in the liver.Cancer Letters,2007;245:134-143.
35 Anja H.Wiese,Johannes Auer,Silke Lassmann,et al.Identification of gene signatures for invasive colorectal tumor cells.Cancer Detection and Prevention,2007;31:282-295.